Phase 2 trial of the fatty acid synthase (FASN) inhibitor TVB-2640 for advanced KRAS mutant non-small cell lung cancer (NSCLC)

Lung Cancer
David Gerber, MD
University of Texas Southwestern Medical Center


Non-small cell lung cancer (NSCLC) with a mutation called KRAS occurs in approximately 40,000 patients in the U.S. each year. Patients with the KRAS mutation have a particularly poor prognosis with a 5-year survival of less than 10%. Despite treatment with chemotherapy and immunotherapy, almost all patients relapse and succumb to progressive disease. Preclinical studies have demonstrated that fatty acid metabolism is a critical requirement of the KRAS mutation. They found NSCLC cells with the KRAS mutation had a high amount of proteins responsible for fatty acid production and when they lost these proteins, it lead to tumor cell death. TVB-2640, a new investigational agent, selectively targets fatty acid synthase, the proteins responsible for fatty acid production. This phase II study will assess if a TVB-2640 can increase the response rate and disease control rate in advanced-stage or metastatic NSCLC patients with the KRAS mutation.

Trial Registration: Identifier: NCT03808558